Literature DB >> 2727475

The bias of the sample proportion following a group sequential phase II clinical trial.

M N Chang1, H S Wieand, V T Chang.   

Abstract

Group sequential testing procedures have seen wide use in Phase II clinical trials. The sample proportion p of responders is the commonly used estimator for the binomial response probability p. It can be shown that p is the maximum likelihood estimator (MLE) of p. It is well known that MLE can be in general (Whitehead) and p in particular (Dupont) biased estimators, if ther computation follows a group sequential procedure. In this paper we numerically investigate the bias of p. We find that the magnitude of the bias of p is less than 0.025 in all cases we investigated. We apply the idea in Whitehead to propose a bias-adjusted estimator that reduces the bias substantially and reduces the mean square error as well in a certain range of p. We also evaluate the uniformly minimum variance unbiased (UMVU) estimator. If one does not mind a bias of 0.025, one may find the sample proportion a suitable estimator for p because of its simplicity and easy explanation. If one is concerned with bias, the bias-adjusted estimator may be a good choice.

Mesh:

Year:  1989        PMID: 2727475     DOI: 10.1002/sim.4780080505

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2012-04-20       Impact factor: 2.486

Review 2.  Sources of bias for single-arm phase II cancer clinical trials.

Authors:  Sin-Ho Jung
Journal:  Ann Transl Med       Date:  2022-09

3.  Proper inference from Simon's two-stage designs.

Authors:  Tatsuki Koyama; Heidi Chen
Journal:  Stat Med       Date:  2008-07-20       Impact factor: 2.373

4.  Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.

Authors:  Junjun Zhao; Menggang Yu; Xi-Ping Feng
Journal:  BMC Med Res Methodol       Date:  2015-06-07       Impact factor: 4.615

Review 5.  Basic design considerations for clinical trials in oncology.

Authors:  S Piantadosi; N Saijo; T Tamura
Journal:  Jpn J Cancer Res       Date:  1992-06

6.  A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.

Authors:  Martin Law; Michael J Grayling; Adrian P Mander
Journal:  Pharm Stat       Date:  2020-08-29       Impact factor: 1.894

7.  What inference for two-stage phase II trials?

Authors:  Raphaël Porcher; Kristell Desseaux
Journal:  BMC Med Res Methodol       Date:  2012-08-06       Impact factor: 4.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.